Epizyme Inc (NASDAQ:EPZM)
| 2.93 Delayed Data As of 4:00pm ET |  -0.345 / -10.55%Today’s Change | 2.93 Today|||52-Week Range 14.30 | -73.07% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $350.1M |
Company Description
Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA.
Contact Information
Epizyme, Inc. 400 Technology Square Cambridge Massachusetts 02139 |
Employees
Shareholders
| Other institutional | 41.15% |
| Mutual fund holders | 40.63% |
| Individual stakeholders | 29.37% |
Top Executives
| Grant C. Bogle | President, Chief Executive Officer, CFO & Director |
| Shefali Agarwal | Executive VP, Chief Medical & Development Officer |
| Jeffery L. Kutok | Chief Scientific Officer & Executive VP |
| John F. Weidenbruch | Secretary, Senior Vice President & General Counsel |
| Aidan Finley | Director-Business Development |
